Autoimmune hemolytic anemia (AIHA) is a rare type of hemolytic anemia characterized by antibody production against self RBCs, leading to destruction of these cells in the spleen and other reticuloendothelial tissues. The disease is generally categorized as warm or cold, depending on the thermal reactivity of the autoantibodies. The etiology is diverse and includes infections, autoimmune diseases, lymphoproliferative disorders, and drugs. The diagnosis is based on laboratory evidence of hemolysis (elevated LDH, indirect bilirubin, reduced haptoglobin) in association with a positive direct antiglobulin test (DAT) or Coombs test. Management involves supportive care, removal of the inciting agent, use of steroids and immunosuppressive agents, and splenectomy in refractory cases.